
Podfolio.one: Earnings Calls decoded; Your Portfolio, Your Bespoke Podcasts
Temporada 1

Workday, Inc. (WDAY) Q2 FY2027: AI ARR hit nearly $600M, surging 200% year over year, supported by 5,500 customers using organic agents, though investors question whether this growth is additive or cannibalizing core bookings and if the revenue miss

Alphabet Inc. (GOOGL) Q2 FY2026: The debate centers on whether AI infrastructure spend signals durable platform shifts or erodes margins and search economics long term — strong cloud momentum, a $514B backlog, and Gemini Enterprise adopti, alongside
Circle Internet Group (CRCL) Q2 FY2026: Management highlighted regulatory moats via OCC and New York trust charters plus BlackRock and DTCC backing for the September 16 Arc Mainnet launch, though skeptics argue competition from Tether and

Salesforce, Inc. (CRM) Q2 FY2027: Management positioned the platform as a stable system of record for multiple AI models, signaling durable efficiency gains and expanded capacity rather than seat cannibalization

Marvell Technology, Inc. (MRVL) Q2 FY2027: Gross margin held.1%, though shares fell over 11% on sell-the-news reaction amid hyperscaler concentration risk

NVIDIA Corporation (NVDA) Q2 FY2027: Networking grew 18% sequentially to become the world's largest, while the Vera CPU achieved a $5B+ TTM run rate and is projected to more than double next year.8x performance gains

Baidu, Inc. (BIDU) Q2 FY2026: Management highlighted robust training and inference demand plus a new Hong Kong robotaxi permit, but noted industry-wide supply constraints and questioned whether monetization can keep pace with spending

General Motors Company (GM) Q2 FY2026: Outlook hinges on simultaneous next-gen Silverado/Sierra launches, Super Cruise subscriptions as a razor-blade model, and GM Defense diversification

Target Corporation (TGT) Q2 FY2026: Management highlighted accelerating momentum in 7 categories representing half of sales plus new AI partnerships, though durability remains uncertain once resets and limited-time collabs fade

Biogen Inc. (BIIB) Q2 FY2026: The Apellis acquisiti, enabling faster-than-expected high-dose SPINRAZA conversion across Japan, Europe, and the US
1 de 9